TEV:F:F-Teva Pharmaceutical Industries Limited (EUR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 15.6

Change

0.00 (0.00)%

Market Cap

USD 18.06B

Volume

420.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-22 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MRKC:F MERCK KGAA NAM.SP.ADR

N/A

USD 73.13B
MRK:F Merck & Company Inc

N/A

USD 72.76B
H6D0:F Haleon PLC

N/A

USD 42.81B
H6D:F Haleon PLC

N/A

USD 42.44B
TKDA:F Takeda Pharmaceutical Company ..

N/A

USD 41.84B
3KY:F HANSOH PHARMAC. HD-00001

N/A

USD 13.31B
RDDA:F Dr. Reddy's Laboratories Limit..

N/A

USD 12.12B
SH0:F Shionogi & Co. Ltd

N/A

USD 11.31B
NB3:F Neurocrine Biosciences Inc

N/A

USD 10.87B
EII:F Eisai Co. Ltd

N/A

USD 10.32B

ETFs Containing TEV:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 70.31% 88% B+ 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 70.31% 82% B 89% A-
Trailing 12 Months  
Capital Gain 59.84% 87% B+ 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 59.84% 80% B- 83% B
Trailing 5 Years  
Capital Gain 140.00% 90% A- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 140.00% 67% D+ 79% B-
Average Annual (5 Year Horizon)  
Capital Gain 10.59% 78% C+ 71% C-
Dividend Return 10.59% 72% C 64% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 36.15% 46% F 33% F
Risk Adjusted Return 29.31% 69% C- 55% F
Market Capitalization 18.06B 97% N/A 90% A-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector